Infusion Providers Alliance endorses the “Protecting Patient Access to Cancer and Complex Therapies Act of 2023”Infusion Providers Alliance2023-09-13T15:50:43+00:00
The Infusion Providers Alliance (IPA) is pleased to provide comments to the 2024 Medicare physician fee schedule proposed ruleInfusion Providers Alliance2023-09-12T16:09:36+00:00
IPA responds to Senate request for stakeholder input regarding the Medicare 340B Drug Discount ProgramInfusion Providers Alliance2023-07-31T22:09:37+00:00
IPA lobbies Congress to add specialty pharmacy transparency language to pending pharmacy benefit manager (PBM) reform legislationInfusion Providers Alliance2023-07-25T12:54:41+00:00
The IPA has cosigned a May 30 letter to Senate and House leadership asking Congress to amend the Inflation Reduction Act by making “providers whole in Medicare’s drug price negotiation process and removing them from the middle of this negotiation process.”Infusion Providers Alliance2023-06-09T18:08:21+00:00
IPA submits hearing testimony to House subcommittee on legislation addressing transparency and competition in health careInfusion Providers Alliance2023-04-28T17:49:18+00:00
7 Provider Organizations Co-sign Letter to CMS Administrator RE: MAC Downcoding of Highly Complex Drug InfusionsInfusion Providers Alliance2022-08-30T22:37:12+00:00
IPA Supports Amendment to Protect Infusion Providers and their Patients from Rx Pricing Provisions of Senate Reconciliation BillInfusion Providers Alliance2022-08-05T14:24:52+00:00
